Human interleukin-4 (hulL-4) has been shown to inhibit the growth in vitro of cells from patients with acute lymphoblastic leukemia (ALL). With the aim of determining whether this cytokine might be useful in the treatment of patients with ALL, the effects of hulL-4 on human B-cell precursor ALL engrafted in severe combined immunodeficient (SCID) mice were examined. The inhibition of ['HI thymidine uptake of primary ALL cells by hulL-4 was maintained following engraftment and passage of leukemia in SCID mice. Five of seven xenograft leukemias showed significant inhibition in vitro by hull-4 at concentrations as low as 0.5 nglmL; furthermore, hulL-4 counteracted the proliferative effects of IL-7. When used to treat two human leukemias engrafted in LTHOUGH TREATMENT of childhood acute lympho-
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Human interleukin-4 (huIL-4), a glycoprotein secreted by activated T lymphocytes and basophils, affects a range of cells including lymphocytes, monocytes, and polymorphonuclear cells.
IL-4 induces naive T-helper cells to differentiate into Th2 cells and is an autocrine growth factor for Th2
IL-4 also has a major role in allergy with the induction of Ig E production, but inhibits the secretion of proinflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF) by monocytes/macrophages and polymorphonuclear cell^.^,^ IL-4 acts as a growth factor for activated mature B lymphocyte~.~,' However, IL-4 suppresses the proliferation of normal and leukemic human B-cell precursors, inducing cell death through apoptosis.8-" This cytokine may therefore be effective therapeutically against lymphoid malignancies.
The severe combined immunodeficient (SCID) mouse, homozygous for the scid mutation on chromosome 16, is deficient in functional T and B lymphocytes and lacks detectable circulating Igs." Primary human ALL, obtained directly from patients, may be readily engrafted in SCID mice and disseminates in a pattern closely resembling the human disLeukemia samples from more than 50% of patients with B-cell precursor ALL, the commonest phenotype," will engraft in SCID mice.I4-l6 Furthermore, human ALL may be then passaged to other SCID mice with reproducible growth characteristics and maintenance of both the immunophenotype and karyotype.'3-'5.'8 In our laboratory we have demonstrated transient suppression of human ALL in the SCID mouse with a brief course of single agent vincristine as would be expected in the clinic.'' Therefore, we consider the SCID mouse as the best available experimental model of both the pattern of disease and the clinical course of a high proportion of patients with B-cell precursor ALL.
We have shown inhibitory effects of huIL-4 on primary and xenograft ALL cells in vitro and have shown that huIL-4 suppressed ALL growth in SCID mice and extended animal survival. SCID mice, hulL-4 200 pglkgld. as a continuous 14-day subcutaneous infusion, suppressed the appearance of circulating lymphoblasts and extended survival of mice by 39% and 108%, respectively, the first demonstration of IL-4 activity against human leukemia in vivo. The mean steady-state hulL-4 level in mouse plasma during the infusion was 1.46 nglmL (SEM L 0.14 nglmL), which was similar to concentrations found to be effective in vitro. ALL cells obtained from mice relapsing after hulL-4 treatment continued to show inhibition by the cytokine in vitro. These data suggest that IL-4 may be useful in the treatment of patients with ALL. 0 1996 by The American Society of Hematology.
MATERIALS AND METHODS
Engraftment of human leukemia in SCID mice. Bone mmow (BM) or peripheral blood (PB) was collected from seven patients with B-cell precursor ALL, including one patient with ALL arising as blast crisis of chronic myeloid leukemia (CML) ( Oxford, UK) was added and incubation continued for a further 10 minutes. Cell suspensions were centrifuged at 250g for 10 minutes then held at 4°C for 90 minutes. The cell pellet was resuspended in medium and mononuclear cells separated from T-cell rosettes by density gradient centrifugation.
In vitro effects of IL-4, IL-7, and the combination of IL-4 with IL-7. Human ALL xenograft cells obtained from mouse spleen (first through fifth passage), with greater than 95% viability assessed by trypan blue exclusion, were incubated in 96-well plates (Falcon 3072; Becton Dickinson, Lincoln Park, NJ) at a concentration of 1 to 2 X 106/mL in RPMI 1640 medium with 10% FCS. huIL-4 (specific activity 10 U/ng; Schering-Plough, Bury St Edmonds, UK) was added to give a final concentration range of 0.1 to 10 ng/mL, with and without 200 U/mL human IL-7 (Immunex, Seattle, WA). Six 200-pL wells were used per group. Plates were incubated at 37°C in 5% 02. 10% CO2, 85% N2. Primary human leukemia cells (ALLl) were likewise incubated with huIL-4 0.1 to 50 ng/mL. After 3 days' incubation, 1 pCi t3H] thymidine (Amersham, Little Chalfont, UK) was added per well and plates incubated for a further 8 hours. Cells were harvested onto glass-fiber filters using an automatic cell harvester (Inotech, Wohlen, Switzerland) and radioactive uptake measured directly from the filters using the Inotech Automatic Filter Counting System. Female SCID mice were irradiated and injected via tail vein with 2 X lo7 fresh human ALL xenograft cells from mouse spleen. Fourteen days later, osmotic pumps (Alzet model 2002; Charles River, Margate, UK) were implanted subcutaneously (sc) to produce a steady 14-day infusion. Pumps were weighed to ensure complete filling. For each experiment, six mice received huIL-4 200 pgikg/d in phosphate-buffered saline (PBS) with 0.1 % bovine serum albumin (Sigma, Poole, UK), and six control mice were implanted with pumps delivering diluent only. After completion of the infusion, pumps were removed and examined for complete delivery of their contents.
Flow cytometry analysis of human leukemia cells in SCID mouse blood. At 7-to 10-day intervals, 20 pL of blood was obtained from mice and collected into 30 pL PBS with 50 U/mL preservativefree heparin. Fluorescein-conjugated antibody to human class 1 HLA (W6/32; Sera-lab, Crawley Down, UK) was added at a concentration of I :20 for 30 minutes on ice. Two milliliters of lysis solution (0.037 g disodium EDTA, 1.0 g potassium bicarbonate, 8.3 g ammonium chloride in 1 L) was then added for 10 minutes. After washing, Treatment of human leukemia in SCID mice using IL-4.
samples were resuspended for flow cytometry analysis using an Ortho Cytoron Absolute flow cytometer (Ortho Diagnostic Systems, Raritan, NJ). The proportion of fluorescein-labeled cells was determined within a large gate encompassing the nucleated mouse and human cell populations. Normal SCID mouse blood was included as a negative control with all analyses.
At day 21, 1 week after commencing huIL-4 treatment, blood samples were obtained from mice for measurement of huIL-4 levels. Samples were immediately centrifuged and plasma removed for storage at -80°C. A human immunoassay kit (Quantikine D4000; R&D Systems, Oxon, UK) and manufacturer's methodology was used to measure huIL-4 levels. The range of the assay was 0.0312 ng/mL to 2 ng/mL.
Measurement of huIL-4 levels in SCID mice.
RESULTS

Inhibition of ALL cell growth in vitro by IL-4.
Using cells obtained at presentation from the patient, the sensitivity of ALLl to incubation with huIL-4 was investigated. At concentrations of 1 nglmL and above, greater than 85% inhibition of [3H] thymidine uptake was observed (Fig 1) .
SCID mice were engrafted with leukemia from 7 patients with B-cell precursor ALL (Table 1) . Single-cell suspensions were prepared from mouse spleen and the effects of in vitro exposure to huIL-4 were studied.
In total, of the seven human ALL xenografts tested, five showed significant inhibition of DNA synthesis by huIL-4 For Fig 2) . Inhibition was also significant with huIL-4 at 0.5 ng/mL but not 0.1 ng/mL (data not shown). As these xenograft cells proliferated poorly in vitro, the lymphoproliferative cytokine IL-7 was added to produce a stimulus for leukemia proliferation and to assess the effects of huIL-4 under such conditions. IL-7 has proliferative effects in vitro on leukemia cells from most patients with ALL.?"." When incubated with human IL-7 200 U/mL used alone, DNA synthesis was increased 1.5-to 3.5-fold compared with controls for 5 of the 7 cases (ALLI-3, 5 , and 6; Fig 2) .
For all cases, when huIL-4 1 ng/mL was added to IL-7 200 U/mL, thymidine uptake was reduced to between 9% and 74% of uptake of IL-7-alone cultures (P < .01). In particular, the addition of hulL-4 counteracted the marked stimulatory effects of IL-7 on the two leukemias (ALLI and 2), which were later treated with hulL-4 in SCID mice. Although huIL-4 alone did not significantly inhibit thymidine uptake of the two Philadelphia chromosome-positive (Ph') ALL cases (ALL5 and 6). nevertheless the cytokine did counteract the proliferative effects of 1L-7 (Fig 2) .
Comparison of the in vitro e&ts of IL-4 on priman, and passaged human leukemia. It was necessary to establish that the sensitivity of ALL cells to growth inhibition by huIL-4 was not altered by passage within SCID mice. The effects of huIL-4 and IL-7 were compared for primary leukemia cells (ALLI) obtained from the patient and ALL1 xenograft samples from the 5th and 22nd passage in SCID mice (Fig 3) . IL-4 produced similar levels of DNA synthesis inhibition in the three samples, both used alone and in combination with IL-7. The stimulatory effects of IL-7 were also retained after multiple passage of the leukemia.
Effects of IL-4 on human ALL engrqfled into SCID mice. The in vivo effects of hulL-4 were tested for two human leukemias engrafted in SCID mice which had been shown to be inhibited by huIL-4 in vitro. These were an early Bcell precursor ALL established from a 36-year-old man (ALLI, sixth passage) and a pre-B ALL established from a 2-year-old female (ALL2, fourth passage). Fourteen days after IV injection of cells, osmotic pumps were implanted sc to deliver a steady 14-day infusion of huIL-4, 200 pg/kg/d. For both leukemias, the appearance of human lymphoblasts in murine PB was delayed and animal survival improved for hull-4-treated animals. For ALL1 , control animals began to show greater than 10% human leukemia cells in the circulation at day 45 (17 days after cessation of the control infusion), whereas for hulL-4-treated animals the appearance of leukemia cells was delayed by a further 56 days (Fig 4A) . The median survival of huIL-4-treated animals improved 108% from 56 days (range 50 to 70) to 116.5 days (range 104 to 140+) (P < .001, Mann-Whitney test), although animals eventually relapsed and died of human leukemia (Fig 4B) .
The appearance of ALL2 human leukemia cells in blood was also delayed in huIL-4-treated animals. At day 21, control animals showed a mean of 13% human cells whereas huIL-4-treated mice showed a mean of 4%. At day 30. levels were 65% and 42%, respectively (Fig 5A) . However, the proportion of human cells in blood was already high for many hull-4-treated animals 2 days after cessation of the hulL-4 infusion. The median survival of huIL-4-treated animals improved 39% from 34.5 days (range 34 to 43) to 48 days (range 47 to 49) (P < .OOl), with all animals dying of human leukemia (Fig 5B) .
Both the control and hurl-4-treated animals had similar leukemic burdens at death or sacrifice as judged by the percentage of circulating leukemia cells and the weight of leukemia-infiltrated spleens. No toxicity of hulL-4 in the mice was noted.
After treatment for a week, mice receiving a constant sc infusion of hulL-4 200 pg/kg/d had a mean plasma hulL-4 level of 1.46 ng/mL (SEM 2 0.14 ng/mL), with a range of 0.96 to 1.98 ng/mL for the six mice tested (Fig 6) . Human IL-4 was not detectable in PB of control mice. To investigate IL-4 levels with bolus dosing, six SCID mice were given daily sc injections of huIL-4 200 pgkg for 1 week and PB samples were taken immediately before and 1 and 4 hours after dosing. The predose level was 0.003 ng/mL, below the range of the assay. One hour after dosing, plasma huIL-4 was 17.2 ng/mL (SEM 2 3.2 ng/mL), but at 4 hours had decreased to 0.14 ng/mL (SEM 2 0.06 ng/mL).
The in vitro sensitivi~ of ALL1 and ALL2 to IL-4 is retained in IL-4-treated animals. For both ALLl and ALL2, human ALL xenograft cells were obtained from spleens of animals that had relapsed after huIL-4 treatment and the sensitivity of these cells to huIL-4 and IL-7 was compared with ALLl and ALL2 cells from untreated animals.
Both ALLl and ALL2 xenograft cells from huIL-4-treated animals continued to show significant inhibition of DNA synthesis by huIL-4 1 .O ng/mL both alone (P < .05) and in combination with IL-7 (P < .01). However, the degree of inhibition was reduced compared with that observed using cells obtained from untreated mice (Fig 7) . IL-4 inhibition of thymidine u p take by untreated ALLl xenograft cells was 82% compared with 40% inhibition of treated ALLl xenograft cells (Fig 7A) . For ALL2 xenograft cells, huIL-4 inhibition wa.. 51% for previously untreated cells and 19% for treated cells (Fig 7B) .
DISCUSSION
We have shown that huIL-4 suppressed human B-cell precursor ALL engrafted in SCID mice and improved animal survival. This finding correlated with the observed effects of IL-4 on ALL cells in vitro.
Primary ALLl cells were inhibited in vitro by huIL-4 0.5 ng/mL and the inhibitory effects were maintained after engraftment and multiple passage of this leukemia in SCID mice. Significant inhibitory effects of huIL-4 were also seen for 5 of 7 human xenograft leukemias established from patients with B-cell precursor ALL, at concentrations of 0.5 ng/mL and above. Similar concentrations of huIL-4 have been reported by Manabe et all' to produce apoptosis of Bprecursor ALL cells when cultured on BM stroma. Under suspension culture conditions, as used in the current study, ALL cells survive poorly. It is possible that in suspension culture a high background rate of apoptosis of leukemic cells masked the effects of IL-4 in some cases.
Clearly there are aspects of both the human and the SCID mouse environment that support proliferation of human ALL. These factors are ill-defined. In humans it is possible that the lymphoproliferative cytokine 1L-7 is involved in ALL cell growth in vivo. Therefore, we studied the effects of costimulation of ALL cells with human IL-7 and huIL-4. The inhibitory effects of huIL-4 continued to be observed in leukemia cells stimulated by IL-7. In two cases IL-4 counteracted the increased DNA synthesis seen with IL-7, whereas IL-4 used alone had shown no effect.
The efficacy of huIL-4 treatment of ALL in vivo was tested using mice engrafted with two xenograft leukemias 
B
The plasma levels of huIL-4 achieved in SCID mice with continuous infusion huIL-4 200 pg/kg/d were between 0.96 and 1.98 ng/mL. These values for effective in vivo concentrations were in agreement with the observed inhibition of xenograft leukemia cells in vitro by huIL-4 0.5 ng/mL. A previous experiment using huIL-4 100 p g k g as a daily bolus sc injection to treat mice engrafted with ALLl failed to show any beneficial effect of huIL-4 in terms of either levels of circulating ALL cells or survival (data not shown). With daily bolus injections high peak levels of huIL-4 were achieved, but within 4 hours had fallen below 0.5 ng/mL. This suggests that continuous exposure to 0.5 to 1.0 ng/ mL concentrations of huIL-4 may be necessary to suppress leukemia in SCID mice, and further suggests that a continuous infusion of huIL-4 may be the appropriate schedule for the treatment of patients with ALL.
Xenograft leukemia cells obtained from huIL-4-treated animals continued to show inhibition by huIL-4 in vitro, although for both leukemias sensitivity had diminished. The continued in vitro inhibition raises the possibility of retreating or prolonging treatment with huIL-4; however, the reduction in sensitivity suggests that huIL-4 alone at the concentrations achieved may not be curative in this model of ALL.
The mechanism of huIL-4 inhibition of human ALL in SCID mice is unclear. In some situations IL-4 activity is mediated through the recruitment of murine effector cells. In a murine model, solid tumor growth was inhibited by enhanced host immunity when murine IL-4 was injected locally22 or when the murine IL-4 gene was transfected into tumor ~e l l s . *~.~~ However, human IL-4 and murine IL-4 share only a 49% homology of amino acid sequence and the activities are highly species specific.2' Furthermore, we have demonstrated huIL-4 inhibition of in vitro cultures of xenograft cells from mouse spleen that contain very few murine cells (4%). Human IL-4 has been shown to induce apoptosis in lymphoblasts" in vitro, and this may be a mechanism of action of huIL-4 against xenograft ALL. In humans, these Human IL-4 has been shown to inhibit a range of human solid malignancies in vitr0z6,z7 and several studies of IL-4 used in patients with solid tumors have been reported, with some favorable tumor response^.^*-^' This is the first demonstration of activity of huIL-4 against primary human leukemia cells grown in SCID mice. These data suggest a use for IL-4 in the treatment of patients with ALL.
As with many cytokines, huIL-4 has a range of side effects when used to treat patients. Flulike symptoms predominate at low-dosage levels and are generally not dose-limiting. However, at doses of 4 to 5 pg/kg/d headache, neurological disturbances, and alterations in liver function may occur whether IL-4 is administered by subcutaneous injectionz8 or IV infusion (Schering-Plough; data on file). Higher daily doses, above 5 pg/kg/d, have been tolerated in some studies,"." although some patients receiving high doses of IL-4 encountered problems of gastrointestinal hemorrhage and cardiac ischemia,3' which may have been related to the cytokine.
There are limited published data regarding the pharmacokinetics of huIL-4 in patients. Subcutaneous injection of huIL-4, 5 pgkg, produced a peak serum IL-4 level of 1 ng/ mL, with levels remaining above 0.25 ng/mL for 8 hours.'' This peak IL-4 level is within the range of 0.5 to 1.0 ng/mL where in vitro antileukemic activity was seen. However, if the cytokine is to be administered by continuous IV infusion then higher daily doses will be needed to maintain therapeutic levels. Clinical trials of IL-4 are required to determine whether patients with ALL can be successfully treated at tolerable doses of the cytokine.
